加拿大主要肺炎链球菌血清型多重耐药分析:SAVE研究2011-15年
该研究评估了2011至2015年加拿大侵袭性肺炎链球菌多重耐药(MDR)与血清型演变的关系,共纳入6207株侵袭性分离株,其中6001株有完整药敏谱。总体MDR率为6.2%(372/6001),从2011年8.5%显著降至2015年5.6%(P=0.0041)。2015年56.3%的侵袭性MDR菌株属于PCV-13疫苗覆盖血清型,但15A、24F和33F等MDR血清型不在现有疫苗中。
要点
- 总体MDR率为6.2%(372/6001),从2011年8.5%显著降至2015年5.6%(P=0.0041)。
- MDR见于32种血清型,以19A(41.7%)和15A(26.6%)为主。
- 2015年56.3%的侵袭性MDR菌株为PCV-13覆盖血清型,但15A、24F、33F不在现有疫苗中。
核心结论
- 2015年56.3%的侵袭性MDR肺炎链球菌为PCV-13疫苗覆盖血清型,PCV-13涵盖最常见血清型19A,但15A、24F和33F等重要MDR血清型不在现有疫苗中。
研究设计与样本
- 加拿大抗菌药物耐药联盟与加拿大公共卫生局国家微生物实验室合作开展的年度SAVE研究,共评估6207株侵袭性肺炎链球菌分离株,全部进行血清分型和药敏试验(按CLSI M07-A10,2015),6001株有完整药敏谱。
- MDR定义为对三类及以上抗菌药物类别耐药(青霉素MIC≥2 mg/L定义为耐药)。
主要发现
- 总体MDR率为6.2%(372/6001),从2011年8.5%显著降至2015年5.6%(P=0.0041)。
- MDR见于32种血清型,以血清型15A和19A为主,分别占MDR分离株的26.6%和41.7%。
- 研究期间血清型19A、7F和33A的总体比例显著下降(P<0.0001)。
- 研究期间血清型7C、8、9N、10A、20、24F、29、31、33F、35B和38的年度比例上升,但其中仅24F和33F的MDR比例较显著(>5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study assessed MDR invasive isolates of Streptococcus pneumoniae, in relation to serotype evolution in Canada between 2011 and 2015 as part of the annual SAVE study. METHODS: As part of a collaboration between the Canadian Antimicrobial Resistance Alliance and Public Health Agency of Canada-National Microbiology Laboratory, 6207 invasive isolates of S. pneumoniae were evaluated. All isolates were serotyped and had antimicrobial susceptibility testing performed, in accordance with CLSI guidelines (M07-A10, 2015). Complete susceptibility profiles were available for 6001 isolates. MDR was defined as resistance to three or more classes of antimicrobial agents (with penicillin MIC ≥2 mg/L defined as resistant). RESULTS: The overall rate of MDR S. pneumoniae was 6.2% (372/6001) in SAVE, decreasing significantly from 8.5% in 2011 to 5.6% in 2015 (P = 0.0041). MDR was observed in 32 serotypes, with serotypes 15A and 19A predominating (26.6% and 41.7% of the MDR isolates, respectively). The overall proportion of serotypes 19A, 7F and 33A decreased significantly (P < 0.0001) throughout the study. The annual proportion of serotypes 7C, 8, 9N, 10A, 20, 24F, 29, 31, 33F, 35B and 38 increased throughout the study; however, among these increasing serotypes, MDR was only notable (>5%) for 24F and 33F. CONCLUSIONS: In 2015, 56.3% of invasive MDR S. pneumoniae were serotypes included in the PCV-13 vaccine. PCV-13 includes the most commonly identified serotype, 19A; however, other increasingly important MDR serotypes, such as 15A, 24F and 33F, are notably not in the currently used vaccines.
引用
- Adam HJ, Golden AR, Karlowsky JA, et al. Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15. J Antimicrob Chemother. 2018. PMID: 29982572. doi:10.1093/jac/dky158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。